|
NYMOX PHARM CORP, (NYMX) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Nymox Pharmaceutical Corporation, through its subsidiaries, engages in the research and development of products for the diagnosis and treatment of Alzheimers disease. The company markets AlzheimAlert, a urinary test that helps physicians in the diagnosis of Alzheimers disease. It also markets NicAlert and TobacAlert tests that use urine or saliva to detect the use of tobacco products. In addition, Nymox develops therapeutics for the treatment of Alzheimers disease; treatments for benign prostate hyperplasia; and anti-bacterial agents for the treatment of urinary tract and other bacterial infections in humans, including a treatment for E. coli O157:H7 bacterial contamination in meat and other food and drink products. The company was founded by Paul Averback in 1989 and is based in St. Laurent, Canada.
|
|
